- Condition: Newly Diagnosed Glioblastoma Multiforme
Intervention: Other: Lapatinib/Temozolomide/radiation
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Melanoma
Interventions: Drug: Doxycycline; Drug: Ipilimumab; Drug: Temozolomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH); National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Condition: Hodgkin Lymphoma, Adult
Interventions: Drug: Brentuximab vedotin; Drug: ABVD Induction
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Seattle Genetics, Inc.
Recruiting - verified May 2012 - Condition: Acute Myeloid Leukemia With 11q23-abnormality in Relapse
Intervention: Drug: Temozolomide
Sponsors: Stanford University; Stanford University; Merck
Not yet recruiting - verified March 2012 - Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin; Drug: Adriamycin, vinblastine, and dacarbazine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Seattle Genetics, Inc.
Recruiting - verified April 2012 - Condition: Metastatic Melanoma
Interventions: Drug: vinblastine; Drug: Cyclophosphamide; Drug: dacarbazine
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center
Recruiting - verified February 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Drug: veliparib; Genetic: gene expression analysis; Genetic: protein analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Gastrinoma; Glucagonoma; Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Recurrent Pancreatic Cancer; Somatostatinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: temozolomide; Biological: bevacizumab
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib; Drug: Temozolomide; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Neuroblastoma
Interventions: Drug: TPI 287; Drug: Temozolomide; Drug: Irinotecan
Sponsors: Van Andel Research Institute; Giselle Sholler; Archer Biosciences, Inc.
Recruiting - verified April 2012 - Condition: Glioblastoma
Interventions: Drug: Phase 1 Dose Escalation; Drug: Phase 1b; Drug: Ancillary Study
Sponsors: Actelion; Actelion
Recruiting - verified December 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: mibefradil dihydrochloride; Drug: temozolomide; Other: 3'-deoxy-3'-[18F]fluorothymidine; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI); Tau Therapeutics LLC
Recruiting - verified April 2012 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012 - Condition: Glioblastoma Multiforme
Interventions: Radiation: Low Dose Fractionated Radiation Therapy (LDFRT); Drug: Temozolomide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified April 2012 - Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin; Drug: doxorubicin hydrochloride; Drug: vinblastine; Drug: dacarbazine; Procedure: quality-of-life assessment; Genetic: DNA analysis; Genetic: RNA analysis; Radiation: fludeoxyglucose F 18; Procedure: positron emission tomography; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: polymorphism analysis
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified November 2011 - Conditions: Nausea; Vomiting; Glioma
Interventions: Drug: Aprepitant and Ondansetron; Drug: Ondansetron
Sponsors: Duke University; Duke University; Merck
Not yet recruiting - verified March 2012 - Conditions: Pancreatic Alpha Cell Carcinoma; Pancreatic Beta Islet Cell Carcinoma; Pancreatic Delta Cell Carcinoma; Pancreatic G-cell Carcinoma; Recurrent Islet Cell Carcinoma
Interventions: Drug: temozolomide; Drug: pazopanib hydrochloride
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified November 2011 - Condition: Glioblastoma Multiforme
Intervention: Drug: Temozolomide, bevacizumab and bortezomib
Sponsors: Emory University; Emory University
Recruiting - verified March 2012 - Condition: Brain Cancer
Interventions: Drug: Temozolomide; Drug: Memantine; Drug: Mefloquine; Drug: Metformin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Condition: Glioblastoma
Interventions: Drug: BKM120 + temozolomide; Drug: BKM120 +temozolomide with/without radiotherapy
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Glioblastoma Multiforme; Anaplastic Glioma
Interventions: Drug: PPX (CT2103); Drug: Temozolomide
Sponsors: Brown University; Debora G. Isdale; Yale University; Milton S. Hershey Medical Center; University of Washington; University of Massachusetts, Worcester; Maine Medical Center
Recruiting - verified May 2012 - Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2012 - Condition: Soft Tissue Sarcoma
Interventions: Drug: Eribulin mesylate 1.4 mg/m2 intravenous; Drug: Dacarbazine of 850 mg/m2, or 1,000 mg/m2, or 1,200 mg/m2 IV
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2012 - Conditions: Recurrent Melanoma; Stage IV Melanoma
Interventions: Drug: temozolomide; Other: flow cytometry; Other: staining method; Procedure: biopsy; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Recurrence of Solid Tumor; Glioblastoma Multiforme; Melanoma
Interventions: Drug: MK-4827; Drug: Temozolomide
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Glioma
Interventions: Drug: LY2157299; Drug: Radiation; Drug: Temozolomide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Hepatocellular Carcinoma
Intervention: Drug: temozolomide + ABT-888
Sponsors: Georgetown University; Georgetown University; Abbott
Recruiting - verified October 2011 - Condition: Melanoma (Skin)
Interventions: Drug: cisplatin; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: temozolomide; Drug: vinblastine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Sarcoma; Desmoplastic Small Round Cell Tumor (DSRCT)
Intervention: Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified March 2012 - Condition: Diffuse Intrinsic Pontine Glioma
Interventions: Drug: Bevacizumab; Drug: Erlotinib; Drug: Temozolomide; Radiation: Irradiation
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; University of California, San Francisco; Children's Hospital Boston; Children's Memorial Hospital; Children's Hospital Los Angeles; University of Utah; Memorial Sloan-Kettering Cancer Center; Seattle Children's Hospital; Children's Hospital Colorad; Doernbecher Children's Hospital; Washington University Children's Hospital; Miami Children's Hospital; Johns Hopkins University; University of Florida; Children's Hospitals and Clinics of Minnesota; Southwestern Regional Medical Center; New York University; University of Rochester; University of Mississippi Medical Center; Louisville Children's Hospital; Children's Healthcare of Atlanta
Recruiting - verified September 2011 - Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Intervention: Drug: Super-Selective Intraarterial Intracranial Infusion of Temozolomide
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012 - Conditions: Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: DNA methylation analysis
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Genentech
Recruiting - verified February 2012 - Condition: Intraocular Melanoma
Interventions: Drug: selumetinib; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: temozolomide; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Melanoma
Intervention: Drug: Temozolomide
Sponsors: Duke University; Duke University; Merck; M.D. Anderson Cancer Center; H. Lee Moffitt Cancer Center and Research Institute
Recruiting - verified February 2012 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012 - PI/II of Temozolomide & Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma MultiformConditions: Glioblastoma; Cancer of Brain and Nervous System; Glioblastoma Multiforme
Interventions: Drug: Temozolomide; Procedure: Stereotactic Radiosurgery
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: temozolomide; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Neuroblastoma
Intervention: Drug: Bevacizumab, Irinotecan and Temozolomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified April 2012 - Conditions: Brain Cancer; Glioblastoma Multiforme
Interventions: Drug: Vorinostat; Drug: Erlotinib; Drug: Temozolomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified February 2012 - Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Recurrent Intraocular Melanoma
Interventions: Biological: recombinant interferon alfa-2b; Drug: dacarbazine; Other: laboratory biomarker analysis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified December 2011 - Condition: Brain Cancer
Intervention: Drug: Temozolomide, bevacizumab, lithium, radiation
Sponsors: New York University School of Medicine; New York University School of Medicine; Genentech; Ohio State University; Atlantic Health System
Recruiting - verified February 2012 - Condition: Malignant Melanoma
Interventions: Drug: Interleukin-2; Drug: Interleukin-2; Drug: Temozolomide
Sponsors: Penn State University; Penn State University
Recruiting - verified May 2012 - Condition: Melanoma
Interventions: Drug: TPI 287; Drug: Temodar (Temozolomide)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Archer Biosciences, Inc.
Recruiting - verified February 2012 - Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention: Drug: Temozolomide and ABT-888
Sponsors: Georgetown University; Georgetown University; Abbott
Recruiting - verified April 2012 - Conditions: Brain Cancer; Choroid Plexus Tumors
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Cyclophosphamide; Drug: Dactinomycin; Drug: Doxorubicin; Drug: Etoposide; Drug: Irinotecan; Drug: Leucovorin; Drug: Methotrexate; Drug: Temozolomide; Drug: Vincristine
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: bortezomib + Temozolomide; Radiation: external beam radiation therapy
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Hodgkin Lymphoma
Interventions: Drug: Rituximab; Radiation: Involved field irradiation
Sponsors: Fondazione Michelangelo; Fondazione Michelangelo
Recruiting - verified February 2011 - Condition: Melanoma
Intervention: Drug: paclitaxel, carboplatin, temozolomide
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified December 2011 - Condition: Refractory Solid Tumors in Children
Intervention: Drug: combination of Irinotecan, vincristine, temozolomide and bevacizumab
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles
Recruiting - verified October 2009 - Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified March 2012 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: methoxyamine; Drug: temozolomide; Genetic: DNA analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Recurrent Glioblastoma Multiforme; Recurrent Gliosarcoma
Intervention: Drug: temozolomide and bevacizumab
Sponsors: Center for Neurosciences, Tucson; Center for Neurosciences, Tucson; Genentech
Recruiting - verified June 2011 - Condition: Central Nervous System Tumors
Interventions: Drug: Bevacizumab; Drug: Irinotecan; Drug: Temozolomide
Sponsors: All Children's Hospital; All Children's Hospital; V Foundation
Recruiting - verified June 2011 - Condition: Neuroendocrine Tumors
Intervention: Drug: Capecitabine and temozolomide
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011 - Condition: Glioblastoma Multiforme/Anaplastic Astrocytoma
Interventions: Drug: temozolomide; Radiation: radiation therapy; Radiation: stereotactic radiotherapy
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified November 2011 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Brain Tumors; Spinal Cord Tumors
Interventions: Drug: Temozolomide; Drug: Lapatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Hodgkin's Lymphoma
Interventions: Drug: R-mabHDI and ABVD; Drug: ABVD
Sponsors: American Scitech International; American Scitech International; ImClone LLC; Bristol-Myers Squibb
Not yet recruiting - verified July 2011 - Condition: Sarcoma
Intervention: Drug: dacarbazine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified December 2011 - Condition: Hodgkin's Disease
Interventions: Drug: R-mabHD; Drug: ABVD
Sponsors: American Scitech International; American Scitech International; ImClone LLC; Bristol-Myers Squibb
Not yet recruiting - verified July 2011 - Condition: Hodgkin Lymphoma
Intervention: Drug: Avastin
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Genentech
Recruiting - verified November 2011 - Conditions: Mixed Gliomas; Malignant Gliomas; Glioblastoma Multiforme
Interventions: Drug: XL765 (SAR245409); Drug: Temozolomide
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Conditions: Melanoma; Non-Small Cell Lung Cancer; Lung Cancer, Non-Small Cell
Intervention: Procedure: Collection of tumor and blood samples
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Hodgkin Lymphoma
Interventions: Drug: Rituximab; Drug: Adriamycin; Drug: Bleomycin; Drug: Vinblastine; Drug: Dacarbazine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified March 2012 - Conditions: Soft Tissue Sarcoma; Mesothelioma
Intervention: Drug: Azacitidine In Combination With Temozolomide
Sponsors: Columbia University; Columbia University; Schering-Plough; Celgene Corporation
Recruiting - verified October 2011 - Condition: Metastatic Melanoma
Intervention: Drug: Proleukin and Dacarbazine
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified September 2011 - Conditions: Glioblastoma Multiforme; Anaplastic Glioma
Interventions: Drug: Vorinostat; Drug: Isotretinoin; Procedure: Surgical Resection; Drug: Temozolomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified March 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: imatinib mesylate; Drug: temozolomide; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2007 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: arsenic trioxide; Drug: temozolomide; Radiation: radiation therapy
Sponsors: Northwestern University; Northwestern University; Cephalon; Cell Therapeutics
Recruiting - verified May 2012
 |
Dacarbazine Clinical Trials |
